Metastatic castrationresistant prostate cancer
-
Poly (ADP- ribose) polymerase inhibitors (PARPi) has been increasingly adopted for metastatic castration-resistance prostate cancer (mCRPC) patients with homologous recombination repair deficiency (HRD). However, it is unclear which PARPi is optimal in mCRPC patients with HRD in 2nd -line setting.
10p vikoch 27-06-2024 2 1 Download
-
To assess the efficacies and potential predictors of a corticosteroid switch in metastatic castrationresistant prostate cancer (mCRPC) patients with biochemical progression on abiraterone acetate plus prednisone (A + P).
9p vimahuateng 26-11-2021 3 1 Download
-
The neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), and circulating tumor cells (CTCs) have been associated with survival in castration-resistant prostate cancer (CRPC). However, no study has examined the prognostic value of NLR and PLR in the context of CTCs.
11p vimahuateng 26-11-2021 15 2 Download
-
With the recent introduction of novel treatment options, real-world data from patients with metastatic castration-resistant prostate cancer (mCRPC) are required to better understand the impact on routine clinical practice.
12p viputrajaya2711 22-06-2020 6 0 Download